Of note, especially in the case of rectal cancer, the tumor material available to laboratories for testing may be limited to only small biopsies, or tissues from partially treated patients containing only few cancer cells, thus making KRAS mutational assessment even more challenging. This evidence concerns the gene KRAS and cancer.